S. Ritland

发表

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

James Rosinski, Paul Delmar, J. Rosinski, 2009, Molecular Cancer Therapeutics.

Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression.

S. Ritland, S. Gendler, 1999, Carcinogenesis.

Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis.

S. Ritland, S. Gendler, G. Rowse, 1998, Cancer research.

Aggressive medulloblastoma with high-level N-myc amplification.

B. Scheithauer, J. Parisi, J. Cunningham, 1994, Mayo Clinic proceedings.

Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice.

S. Ritland, S. Gendler, G. Rowse, 1997, Cancer research.

A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.

N. Fotouhi, D. Heimbrook, J. Reidhaar-Olson, 2008, Cancer research.

Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.

J. Rosinski, S. Ritland, L. Luistro, 2012, International journal of oncology.

Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression.

D. Bostwick, S. Thibodeau, S. Ritland, 1995, Cancer research.

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

R. Salazar, D. Bissett, S. Ritland, 2004, Clinical Cancer Research.

Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.

A. Weaver, J. Morrow, S. Ritland, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes

S. Ritland, S. Zhou, M. Palmisano, 2020, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

S. Ritland, M. Sherman, K. Attie, 2016 .

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia

S. Ritland, S. Zhou, M. Palmisano, 2020, Journal of clinical pharmacology.

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

S. Ritland, M. Sherman, K. Attie, 2016 .

Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo‐astrocytomas

P. Kelly, B. Scheithauer, J. O'fallon, 1992, Genes, Chromosomes and Cancer.

Region‐specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma

V. Ganju, S. Ritland, D. Jenkins, 1995, Genes, chromosomes & cancer.

Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.

L. Hartmann, W. Cliby, S. Ritland, 1993, Cancer research.

Human epithelial ovarian cancer allelotype.

L. Hartmann, W. Cliby, S. Ritland, 1993, Cancer research.

Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas

B. Scheithauer, S. Ritland, R. Jenkins, 1992, Genes, chromosomes & cancer.

Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers.

S. Ritland, R. Jenkins, I. Hay, 1991, The Journal of clinical investigation.

Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury.

W. Karnes, L. Burgart, A. Bridges, 2000, Cancer research.

Use of fluorescence in situ hybridization to detect loss of chromosome 10 in astrocytomas.

S. Ritland, R. Jenkins, J. Herath, 1995, Journal of neurosurgery.

Low-Grade and High-Grade Epithelial Ovarian Carcinomas Comparison of Loss of Heterozygosity Patterns in Invasive Updated

L. Hartmann, W. Cliby, S. Ritland, 2007 .

A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.

J. Crowley, D. Reinke, R. Maki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PKC isoforms in intestinal mucosa and adenomas of APCMIN mice

W. Karnes, L. Burgart, S. Ritland, 1998 .

Adenoma-specific alterations of protein kinase C isozyme expression in Apc(MIN) mice.

W. Karnes, L. Burgart, S. Ritland, 2000, Cancer research.